Pneumotoxicity associated with immune checkpoint inhibitor therapies

Vickie R. Shannon
2017 Current opinion in pulmonary medicine  
Advances in the immunotherapy of cancer have prolonged survival for cancer patients, but the clinical and financial impact of treatments must be considered in determining the overall clinical utility and economic value of therapeutic agents. Quality-adjusted life years and incremental cost-effectiveness ratios are clinical and economic metrics that can be used to evaluate the value of immune checkpoint inhibitors. This Commentary provides perspective on the limitations, benefits, and potential
more » ... its, and potential enhancement of this approach to support value-based medicine.
doi:10.1097/mcp.0000000000000382 pmid:28403039 fatcat:micu4bfptbdltizgheibikitwi